22 Apr 2015 07:00
Â
TyraTech, Inc.
("TyraTech" or the "Company")
Â
Director's Dealings
Â
TyraTech, Inc. (AIM: TYR and TYRU), a natural life sciences company, announces that, it was notified on 21 April 2015, Mr Alan Reade and his wife, Mrs Alyson Reade, sold 555,780 Common shares of US$0.001 per share (AIM: TYR) ("TyraTech shares"); at a price of 5.14 pence per TyraTech share.
Â
Mr & Mrs Reade then immediately repurchased 588,740 Common shares at 5.15 pence per TyraTech share; these shares being acquired equally into their respective ISA accounts.
Â
Following these transactions, Alan Reade's beneficial interest in the Company has increased by 32,960 TyraTech shares to 12,733,616 TyraTech shares representing approximately 4.87% of the Company's issued share capital.
Â
Enquiries:
Â
TyraTech Inc.Alan Reade, Non-Executive ChairmanBruno Jactel, Chief Executive Officer Vincent T. Morgus, Chief Financial Officer & Treasurer  |   Tel: +1 919 415 4340 Tel: +1 919 415 4287 |
SPARK Advisory Partners Limited, Nominated Adviser Matt Davis / Mark Brady  | Tel: +44203 368 3552 Tel: +44203 368 3551  |
Allenby Capital Limited , Joint BrokerChris Crawford | Â Tel: +44 20 3328 5656 |
Whitman Howard Limited, Joint BrokerRanald Mc-Gregor Smith / Niall Devins | Â Tel: +44 20 7659 1240 Â |
Walbrook, Financial PR and IRGuy McDougall/ Nick Rome | Â Tel: +44 20 7933 8790 |
Â